Long-Acting Injectable HIV Regimen Effective in Maintaining Viral Suppression
ViiV Healthcare announced positive 48-week data from the phase 3 studies evaluating a long-acting injectable formulation of cabotegravir + rilpivirine in patients with HIV.
